Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
08 November 2024 | Story Jacky Tshokwe | Photo Supplied
Kingdom Vision Foundation 2024
The Kingdom Vision Foundation (KVF) management team took part in the annual Social Impact Innovation Awards organised by the SAB Foundation.

In September, the Kingdom Vision Foundation (KVF) management team took part in the annual Social Impact Innovation Awards, organised by the SAB Foundation. This competition included a three-day workshop, during which participants received mentorship on enhancing their business models to maximise sustainable impact. Participants also crafted a four-minute business pitch, which they delivered to a panel of independent judges from sectors such as business, health, education, and government. At the end of the workshop, winners were chosen based on the impact of their innovation, the strength of their business model, and the likelihood of future success.

On 10 October, the management team attended the Innovation Awards Ceremony, where KVF was honoured with the Development Award worth R700 000. In addition to the grant, KVF will participate in a 15-month business coaching and mentorship programme in 2025, through which the SAB Foundation’s coaching team will support them in expanding and scaling their impact across South Africa.

The funding will enhance both the Kovsie Health and Anchor of Hope eye clinics, which are collaborating with the University of the Free State (UFS) Department of Optometry to provide affordable eye care to thousands of students and community members. The project aims to improve the quality of education for Optometry students, helping them experience the positive change they can drive through social impact. KVF’s vision includes a future at Kovsie Health where every student’s visual needs are met, regardless of financial constraints, and a thriving Anchor of Hope clinic that brings the gift of sight and renewed hope to rural communities around Bloemfontein.

News Archive

Nano research at the UFS opens door to smart drugs
2011-06-27

 

Prof. Lodewyk Kock, outstanding professor in our Department of Microbial, Biochemical and Food Biotechnology

Novel antifungal, anticancer and anti-malaria drugs that have been identified in the research of Prof. Lodewyk Kock, outstanding professor in the Department of Microbial, Biochemical and Food Biotechnology at our university, will be disclosed later this year at major international conferences in Asia, Europe and the USA. Prof. Kock will be the keynote speaker at these conferences. 

His presentations will be based on the department’s discovery of yeast assays linked to a new nanotechnology for medicine. The assays were recently discovered by his group and can be applied in the development of novel antifungal, anticancer and anti-malaria drugs.
 
Prof. Kock’s focused research at the university, which now also includes his novel nanotechnology for Biology, began in 1982 in collaboration with Prof. Pieter van Wyk (Centre for Microscopy). He recently collaborated with Prof. Hendrik Swart (Department of Physics).
 
Prof. Kock says the development of novel anti-malaria drugs in particular is getting attention across the world due to the high rates of morbidity and mortality caused by the disease worldwide. Approximately 225 million people are infected annually and about a million (many in Africa) die each year. “Many potential smart drugs have been identified with this research and should now be tested further,” says Kock.
  
These new drugs will be disclosed during Prof. Kock’s keynote addresses at the International Conference and Exhibition on Pharmaceutical Regulatory Affairs in Baltimore, USA, from 6 to 7 September 2011, the Medichem 2011 in Beijing, China from 9 to 11 August 2011 and the XVI Congress of European Mycologists in Greece, from 19 to 23 September 2011.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept